Akers Biosciences (NASDAQ: AKER)

 Fact Sheet  Research Report

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of six proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. AKER has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, positioning the Company to be a major competitor in diagnostics globally.

Find a broker to begin trading AKER now

Investment HighlightsValue Proposition
Company Name Akers Biosciences
Market/Symbol NASDAQ: AKER
Recent Price
Market Cap $9.81M
Avg. Daily Vol. (3m) 38,059
Price/Book N/A
Price/Cash Flow 45x
As of Dec. 8, 2016
*Source: QuoteMedia


Begin trading AKER

 Find Broker

Recent Company Videos


Akers Biosciences: Rapid Revenue Growth for Point-of-Care Medical Diagnostics Company

Feb. 25, 2015

Dave Gentry, host of "The RedChip Money Report: Small Stocks Big Money," interviews Dr. Raymond Akers, Founder and CEO of Akers Biosciences, Inc ...


Investment Highlights


Completed capital raise provides funds to develop sales and marketing team; expecting growing revenues from eight commercialized tests

Six proprietary platform technologies enable rapid, cost-efficient new product launches

Akers currently has 4 PIFA® products commercialized and five in clinical/commercial development

Agreement with Medline Industries Inc. to market/distribute its PIFA Heparin Tests directly to hospitals and surgery centers in the U.S.

Akers currently has 4 PIFA® products commercialized and five in clinical/commercial development

Agreement with Medline Industries Inc. to market/distribute its PIFA Heparin Tests directly to hospitals and surgery centers in the U.S.

Agreement with Typenex Medical, LLC to distribute its PIFA Heparin Tests throughout the U.S

Asia-Pacific region and Eastern Europe experiencing double the growth in IVD market compared to rate of global pharmaceutical industry

Value Proposition


AKER’s currently has 11 core tests in large market segments, such as alcohol breathalyzers, diabetes, health and wellness, respiratory diseases, infectious diseases, drug allergies, and cholesterol. The tests can be performed rapidly and affordably, which is crucial given the importance of cost control in healthcare. Many of these tests are already in the market or are nearing market entry, giving the Company substantial potential for near-term revenue growth. Following AKER’s recent capital raise, the Company is trading near net cash ($18.6M market cap vs. $12.8 million in net cash), providing an attractive risk/reward for investors. The Company is also extremely undervalued when compared to the market caps of other in-vitro diagnostics companies.

Akers Biosciences Latest News


Ask the CEO



Meet The Management Team

Raymond F. Akers Jr

Executive Chairman

Patrice Laterra McMorrow

Vice President of Marketing

Gary Rauch

Financial Controller

AKER Research

Revenue increased 32% YoY. In 3Q14, AKER reported revenue of $453,313, a 32% YoY increase as compared to 3Q13 revenue of $344,709. The growth was primarily driven by U.S. sales of PIFA… Read More

Nov. 13, 2014

For over two decades RedChip Companies has been writing research on small-cap stocks. RedChip was the first to put independent research coverage on Starbucks in 1992. Our research analysts, CFAs, include financial models and target prices based on industry competitors. Our analysts cover dozens of stocks with a focus on healthcare, technology, social media, and consumer goods.

RedChip Companies research reports are distributed to 60,000 opt-in retail, institutional, and accredited investors.

RedChip Direct Investment Opportunities For Private and Public Companies

Receive AKER Email Alerts

*By entering your information you agree to our privacy policy.


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market